AML Clinical Trials in New Haven, Connecticut

4 studies are recruiting for aml in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut
    Locations
    45 in total
    Run by
    Kura Oncology, Inc.

    See if you can join NCT06001788 on ClinicalTrials.gov

  2. A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multicenter, genetically-randomized, controlled, Phase 3 study evaluating the efficacy and safety of T-cell receptor-engineered donor T cells targeting HA-2 (TSC-101) administered following reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in participants with …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Yale, New Haven, Connecticut
    Locations
    26 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT07702578 on ClinicalTrials.gov

  3. A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

    This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with A…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Yale, New Haven, Connecticut
    Locations
    21 in total
    Run by
    TScan Therapeutics, Inc.

    See if you can join NCT05473910 on ClinicalTrials.gov

  4. Revumenib in Combination With 7+3 + Midostaurin in AML

    This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaur…

    Stage
    Phase 1
    Ages
    18 to 75
    Site
    Yale Cancer Center, New Haven, Connecticut
    Locations
    2 in total
    Run by
    Richard Stone, MD

    See if you can join NCT06313437 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.